LIPELLA PHARMACEUTICALS INC.
LIPODrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
LP-10 (Liposomal Tacrolimus)
Oral Lichen Planus
LP-10
Hemorrhagic Cystitis
LP-08 80mg
Interstitial Cystitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LP-10 (Liposomal Tacrolimus) | Phase 2 | Oral Lichen Planus | - | - |
LP-10 | Phase 2 | Hemorrhagic Cystitis | - | - |
LP-08 80mg | Phase 2 | Interstitial Cystitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in LIPELLA PHARMACEUTICALS INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in LIPELLA PHARMACEUTICALS INC.'s (LIPO) pipeline across Phase 2. Its lead program is LP-10 (Liposomal Tacrolimus) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LIPELLA PHARMACEUTICALS INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for LIPELLA PHARMACEUTICALS INC. (LIPO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LIPO biotech catalysts?→
Add LIPO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LIPELLA PHARMACEUTICALS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.